255 related articles for article (PubMed ID: 29222829)
41. Disseminated erythema with intense and selective inflammation of sweat gland and lichenoid drug eruption during nivolumab therapy.
Matsumoto Y; Kadono T; Matsuoka M; Kawakami T; Furuya N; Doi M; Hoshikawa M; Soma Y
J Dermatol; 2018 Feb; 45(2):e33-e34. PubMed ID: 28984022
[No Abstract] [Full Text] [Related]
42. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
43. A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma.
Igari S; Yamamoto M; Kikuchi N; Ohtsuka M; Yamamoto T
An Bras Dermatol; 2024; 99(3):450-451. PubMed ID: 38307808
[No Abstract] [Full Text] [Related]
44. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
45. Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer.
Kerkemeyer KLS; Lai FYX; Mar A
Australas J Dermatol; 2020 May; 61(2):180-182. PubMed ID: 31808542
[No Abstract] [Full Text] [Related]
46. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
[TBL] [Abstract][Full Text] [Related]
47. Pembrolizumab-Related Enophthalmos.
Manta A; Goldberg RA
Ophthalmology; 2020 Jan; 127(1):121. PubMed ID: 31864472
[No Abstract] [Full Text] [Related]
48. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
49. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
Nardin C; Borot S; Beaudoin MA; Cattin F; Puzenat E; Gauthier AS; Schillo F; Borg C; Aubin F
Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624
[TBL] [Abstract][Full Text] [Related]
50. Multiple "halo nevi" occurring during pembrolizumab treatment for metastatic melanoma.
Nicolétis-Lombart I; Kervarrec T; Zaragoza J; Machet MC; Samimi M
Int J Dermatol; 2019 Jun; 58(6):739-741. PubMed ID: 30229873
[No Abstract] [Full Text] [Related]
51. [Vulvovaginal complaints, dyspareunia and oral mucosa abnormalities: erosive lichen planus].
Mous HV; Helmerhorst TJ; den Hollander JC; van der Meijden WI
Ned Tijdschr Geneeskd; 2002 May; 146(19):881-5. PubMed ID: 12043442
[TBL] [Abstract][Full Text] [Related]
52. [Successful combination of topical corticosteroids and trichloroacetic acid for the treatment of verrucous lichen planus].
Lahlou F; El Fatoiki F; Hali F; Chiheb S
Ann Dermatol Venereol; 2020 Apr; 147(4):293-297. PubMed ID: 32164922
[TBL] [Abstract][Full Text] [Related]
53. PD-1 inhibitor induced alopecia areata.
Guidry J; Brown M; Medina T
Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
[TBL] [Abstract][Full Text] [Related]
54. Therapy-resistant folliculitis decalvans and lichen planopilaris successfully treated with adalimumab.
Kreutzer K; Effendy I
J Dtsch Dermatol Ges; 2014 Jan; 12(1):74-6. PubMed ID: 24124928
[No Abstract] [Full Text] [Related]
55. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
[No Abstract] [Full Text] [Related]
56. Hypothyroid ataxia complicating monoclonal antibody therapy.
Badran A; Moran C; Coles AJ
Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
[TBL] [Abstract][Full Text] [Related]
57. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
Yatim N; Mateus C; Charles P
Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453
[TBL] [Abstract][Full Text] [Related]
58. Phosphor-signal transducers and activator of transcription 1 signaling in mucosal lichen planus developing from metastatic bladder cancer treated with pembrolizumab.
Tamabuchi E; Fujimura T; Lyu C; Aiba S
Dermatol Ther; 2021 Jul; 34(4):e14961. PubMed ID: 33913225
[No Abstract] [Full Text] [Related]
59. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
[TBL] [Abstract][Full Text] [Related]
60. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.
Sepúlveda M; Martinez-Hernandez E; Gaba L; Victoria I; Sola-Valls N; Falgàs N; Casanova-Molla J; Graus F
Muscle Nerve; 2017 Dec; 56(6):E162-E167. PubMed ID: 28439919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
